Percutaneous Aortic Valve Replacement for Severe Aortic Stenosis in High-Risk Patients Using the Second- and Current Third-Generation Self-Expanding CoreValve ProsthesisDevice Success and 30-Day Clinical Outcome
Eberhard Grube, MD, FACC*,1,*,
Gerhard Schuler, MD, FACC ,
Lutz Buellesfeld, MD*,
Ulrich Gerckens, MD*,
Axel Linke, MD,
Peter Wenaweser, MD*,
Barthel Sauren, MD*,
Friedrich-Wilhelm Mohr, MD,
Thomas Walther, MD,
Bernfried Zickmann, MD*,
Stein Iversen, MD*,
Thomas Felderhoff, MD*,
Raymond Cartier, MD and
Raoul Bonan, MD, FACC,1
* HELIOS Heart Center Siegburg, Siegburg, Germany
Heart Center Leipzig, Leipzig, Germany
Institut de Cardiologie de Montreal, Montreal, Canada.
View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Hemodynamic Tracing Before and After CoreValve
Example of simultaneous left ventricular and aortic hemodynamic tracing at baseline and immediately after implantation of prosthesis.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Mean Aortic Pressure Gradients
Mean gradient pre- versus postimplantation of prosthesis versus 30-day follow-up (for patients with procedural success). PVR = percutaneous valve replacement.
|
|
|
